Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: A combined analysis of 3 pivotal, randomised, phase 3 trials
European Journal of Cancer2012Vol. 48(16), pp. 3082–3092
Citations Over TimeTop 1% of 2012 papers
Allan Lipton, Karim Fizazi, Alison Stopeck, David H. Henry, Janet E. Brown, Denise A. Yardley, Gary Richardson, Salvatore Siena, Pablo Maroto, Michael Clemens, Boris Bilynskyy, Veena Charu, Philippe Beuzeboc, Michael Rader, María Eugenia Ibarrarán Viniegra, Fred Saad, Chunlei Ke, Ada Braun, Susie Jun
Related Papers
- → Improvement of renal function by changing the bone-modifying agent from zoledronic acid to denosumab(2016)9 cited
- → Breast cancer bone metastases: denosumab or zoledronic acid?(2011)4 cited
- → Trends in the use of bone agents in metastatic cancer.(2013)
- → [Incidence of Antiresorptive Agent-Related Osteonecrosis of the Jaw in Urologic Cancers].(2022)
- → 泌尿器癌患者における骨吸収抑制剤関連顎骨壊死の発生頻度の検討(2022)